Mevion Medical Systems is set to launch a new Hyperscan system, claimed to be the world’s first proton therapy solution that can deliver pencil beam scanning at high-speed.
The Hyperscan technology is built on the MEVION S250 proton therapy platform, which has been in operation since December 2013.
Go deeper with GlobalData
The system offers rapid volumetric and layer rescanning, streamlined image-based clinical workflow, sub-millimeter position tracking, and beam gating connectivity.
By using a sharp beam of radiation, the patented technology of Hyperscan allows precise delivery of radiation, with the tumour being volumetrically scanned in few seconds, said Mevion.
The existing pencil beam delivery systems are sensitive to motion, while Hyperscan’s fast beam delivery is said to be less sensitive to patient and tumor motions, which enables better treatment.
See Also:
Mevion Medical Systems president and CEO Joseph Jachinowski said: "Hyperscan enables treatment with fine precision at tremendous speed and with uncompromised beam quality"
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData"This new technological advance will help providers deliver the best possible cancer care to the patients who need it most."
The company will debut the Hyperscan system at the 56th annual meeting of the American Society for Radiation Oncology, which will be held at San Francisco, US, between 14-16 September.
The US Food and Drug Administration (FDA) has not yet approved Hyperscan for clinical use.
Image: Hyperscan debuts at the 56th annual meeting of the American Society for Radiation Oncology in San Francisco. Photo: courtesy of Business Wire.
